The Antibiotic Treatment of Severe Community-Acquired Pneumonia Admitted to the Critical Care Unit

ABSTRACT

Community-acquired pneumonias (CAP) are still caused by Streptococcus pneumoniae, Hemophilus influenzae, or Moraxella catarrhalis. Legionella and Chlamydia pneumoniae have been defined as important atypical pathogens causing CAP. Klebsiella causes CAP primarily in patients with chronic alcoholism or in chronic care facilities. Normal hosts do not present with ``unusual pathogens'' e.g., Staphylococcus aureus or Pseudomonas aeruginosa. The clinical severity of a bacterial pneumonia has important prognostic implications and predicts admission to intensive care units, duration of therapy, and complications. The factors that determine the severity of a CAP are less related to the pathogen than the underlying cardiopulmonary status of the patient as well as the patient's humoral immunity. Relatively avirulent pathogens may result in severe CAP in patients with diminished/absent splenic function or significant cardiopulmonary disease. A critical concept is to appreciate that the selection of antimicrobial therapy is not dependent on co-morbidities since the antimicrobial therapy is directed against the pathogen and not the co-morbidities. Therefore the treatment of CAP, whether moderate or severe is with the same antibiotic at the same dose. Many antibiotic regimens are equally efficacious in the treatment of CAP. The most cost effective optimal regimen covers both typical and atypical pathogens, e.g., levofloxacin, and is currently the preferred antibiotic approach to moderate or severe CAP in the CCU.

KEYWORD

Severe community-acquired pneumonia - CAP in the CCU - antibiotic treatment of CAP

REFERENCES

• 1 Moine P, Vercken J-P, Chevret S. Severe community acquired pneumonia.  Chest . 1994;  105 1487-1495
• 2 MacFarlane J T, Finch R G, Ward M J. Hospital study of adult community-acquired pneumonia.  Lancet . 1982;  2 255-258
• 3 Marrie T J, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: Five year prospective.  Rev Infect Dis . 1989;  11 586-599
• 4 Bartlett J G, Mundy L M. Community-acquired pneumonia.  N Engl J Med . 1995;  333 1618-1624
• 5 Cunha B A, Ortega A M. Atypical pneumonias.  Postgrad Med . 1996;  99 123-132
• 6 Cunha B A. Community-acquired pneumonia: Antimicrobial therapy.  Postgrad Med . 1996;  99 109-122
• 7 Fang G D, Fine M, Orloff J. New and emerging etiologies for community-acquired pneumonia with implication for therapy: A prospective multicenter study of 359 cases.  Medicine . 1990;  69 307-316
• 8 Garibaldi R A. Epidemiology of community-acquired respiratory tract infections in adults: Incidence, etiology, an impact.  Am J Med . 1985;  78 32-37
• 9 Janssens J P, Gauthey L, Hermmann F. Community-acquired pneumonia in older patients.  J Am Geriatr Soc . 1996;  44 539-544
• 10 Karalus N C, Cursons R T, Leng R A. Community-acquired pneumonias: Etiology and prognostic index evaluation.  Thorax . 1991;  46 413-418
• 11 Klimek J J, Ajemian E, Fontecchio S. Community-acquired bacterial pneumonia requiring admission to the hospital.  Am J Infect Control . 1983;  11 78-82
• 12 Farr B M, Sloman A J, Fisch M J. Predicting death in patients hospitalized for community-acquired pneumonia.  Ann Intern Med . 1991;  115 428-436
• 13 Fine M J, Orloff J J, Arisumi D. Prognosis of patients hospitalized with community-acquired pneumonia.  Am J Med . 1990;  88 5
• 14 Fine M J, Hanusa B H, Lave J R. Comparison of medical groups admission severity groups and a pneumonia-specific severity index for patients hospitalized with community-acquired pneumonia.  J Gen Intern Med . 1995;  10 359-368
• 15 Fine M J, Smith M A, Carson C A. Prognosis and outcomes of patients with community-acquired pneumonias.  JAMA . 1996;  274 134-141
• 16 Fine M J, Hough L J, Medsger A R. The hospital admission decision for patients with community-acquired pneumonia.  Arch Intern Med . 1997;  157 36-44
• 17 Holmberg H. Aetiology of community-acquired pneumonia in hospital-treated patients.  Scand J Infect Dis . 1987;  19 491-501
• 18 Leroy O, Santre C, Beuscart C. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit.  Intensive Care Med . 1995;  21 24-31
• 19 MacFarlane J T. Adverse prognostic factors in pneumonia.  Thorax . 1983;  38 231
• 20 Cunha B A. The antibiotic treatment of community-acquired, atypical and nosocomial pneumonias.  Med Clin North Am . 1995;  79 581-598
• 21 Cunha B A. Antibiotic treatment of sepsis.  Med Clin North Am . 1995;  79 551-558
• 22 Cunha B A. Atypical pneumonias. In: Conn RB, Borer WZ, Snyder JW, eds. Current Diagnosis 9 Philadelphia: W B Saunders, 1997: 311-312
• 23 Quenzer R U, Guay D RP. Antimicrobial management strategies for patients with community-acquired respiratory tract infections.  Curr Ther Res . 1995;  56 466-477
• 24 Siegel R E, Halpern N A, Almenoff P L. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia.  Chest . 1996;  110 965-971
• 25 Cunha B A. Severe community-acquired pneumonia.  Crit Care Clin . 1998;  14 105-118
• 26 Cunha B A. Intensive care, not intensive antibiotics.  Heart Lung . 1994;  23 361-362
• 27 Cunha B A. Community-acquired pneumonia in patients with HIV.  Drugs for Today . 1998;  31
• 28 Cunha B A. Antibiotic resistance: Control strategies.  Crit Care Clin . 1998;  8 309-328
• 29 Cunha B A. The extrapulmonary manifestations of community-acquired pneumonias.  Chest . 1998;  112 945
• 30 Cunha B A. Current concepts in the antimicrobial therapy of community-acquired pneumonia.  Drugs for Today . 1998;  34 107-123
• 31 Marrie T J, Lav C Y, Wheeler S L. A controlled trial of a critical pathway for treatment of community acquired pneumonia.  JAMA . 2000;  283 749-7551